24 citations,
January 2018 in “International Journal of Trichology” Tofacitinib helped regrow hair in patients with alopecia, with few side effects.
2 citations,
November 2023 in “Acta dermato-venereologica” Tofacitinib is effective and safe for treating alopecia areata with a good drug survival rate.
2 citations,
June 2023 in “Indian journal of dermatology, venereology, and leprology” Janus kinase inhibitors can regrow hair in alopecia areata but may cause side effects and hair loss may return if treatment stops.
1 citations,
April 2023 in “Frontiers in Immunology” New treatments for hair loss from alopecia areata may include targeting immune cells, using stem cells, balancing gut bacteria, applying fatty acids, and using JAK inhibitors.
April 2024 in “International journal of molecular sciences” Alopecia areata and vitiligo share immune system dysfunction but differ in specific immune responses and affected areas.
January 2024 in “Dermatologic therapy” Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
March 2017 in “Current dermatology reports” Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.
67 citations,
July 2011 in “Clinical, cosmetic and investigational dermatology” The document suggests a personalized treatment plan for alopecia areata based on the patient's age and hair loss severity, using a range of therapies ranked by effectiveness and safety.
40 citations,
September 2019 in “World journal of clinical cases” An elderly man's hair grew back after a treatment that transferred healthy gut bacteria.
38 citations,
March 2017 in “Expert Opinion on Investigational Drugs” Bimatoprost is promising for treating some types of hair loss but needs more testing for androgenetic alopecia.
26 citations,
October 2016 in “American journal of clinical dermatology” New treatments like JAK inhibitors show promise for reversing alopecia areata.
13 citations,
September 2022 in “Frontiers in immunology” Ifidancitinib, a JAK inhibitor, effectively regrows hair in mice with alopecia by tiring out harmful T cells.
8 citations,
September 2015 in “Clinics in Dermatology” Hair loss in children is diagnosed and treated differently than in adults, with different common causes and a focus on less invasive methods.
3 citations,
April 2019 in “Journal of Dermatological Treatment” Caffeine shows promise for treating some types of hair loss, but more research is needed.
June 2024 in “Indian Dermatology Online Journal” Topical tofacitinib is effective and safe for treating alopecia areata.
November 2023 in “Aktualʹnì problemi sučasnoï medicini” The guidelines suggest using various treatments, including antidepressants and steroids, for alopecia areata and discuss the condition's genetic and immune aspects.
September 2023 in “Acta dermato-venereologica” Tofacitinib is a safe and effective treatment for hair loss in children with Alopecia Areata.
Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.
53 citations,
July 2018 in “Drug design, development and therapy” Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.
46 citations,
October 2018 in “JCI insight” CD8+ T cells are involved in alopecia areata and may cause disease relapse.
14 citations,
March 2022 in “Journal of inflammation research” Baricitinib shows promise as a new treatment for certain skin conditions like alopecia areata.
9 citations,
October 2018 in “Journal of Cosmetic and Laser Therapy” Using methods like lasers and microneedling with drugs can improve hair regrowth for alopecia, but more research is needed on safety and best practices.
August 2024 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.
January 2023 in “Indian Dermatology Online Journal” No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.
1 citations,
October 2018 in “InTech eBooks” Only minoxidil and finasteride are FDA-approved for hair loss, with other treatments available but less effective or with side effects.
37 citations,
October 2014 in “JAMA dermatology” A woman with severe hair loss was successfully treated with the drug adalimumab.
43 citations,
June 2018 in “Clinics in dermatology” People with atopic dermatitis are more likely to develop other skin conditions due to shared genetics and immune pathways.
59 citations,
March 2020 in “Journal of Biomedical Science” Understanding how hair follicle stem cells work can help find new ways to prevent hair loss and promote hair growth.
May 2019 in “Australasian Journal of Dermatology” The document discusses hair and nail conditions, updates on treatments for alopecia, and controversies around finasteride use.
26 citations,
January 2019 in “Expert Opinion on Investigational Drugs” New treatments for hair loss show promise, but more research is needed to confirm their safety and effectiveness.